BMET-37 PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS...

Por Ahn, Myung-Ju, Kim, Dong-Wan, Martin, Paul, Davison, Chris, Yang, Zhenfan, Jiang, Haiyi, Yang, James Chih-Hsin
Publicado no Neuro Oncol (2015)